Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. (Q46947501)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2006

Language	Label	Description	Also known as
English	Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.	scientific article published in April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

author name string

Branford S

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

Moore S

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

Hughes TP

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

publication date

1 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

20

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

664-670

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

RE: Bain B.J. (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clinical and Laboratory Haematology26, 315-318.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Bone marrow biopsy morbidity and mortality: 2002 data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Clinical significance of Y chromosome loss in hematologic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

21 January 2018

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic analysis of mosaicism in 53 women with Turner syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Extensive cytogenetic studies of clonality following interferon-alpha therapy in chronic myeloid leukemia occurring in monosomic cells in a patient with Turner syndrome mosaic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404139

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404139

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16482210

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46947501&oldid=2213413369"